The new study published in Nature Biotechnology validates all of the software’s germline algorithms
A large US community hospital system examines reporting and follow-up for germline variants in advanced cancer patients
Laboratory managers on three continents praise the sequencers’ ease of use, speed, and room-temperature reagent shipping and storage
A 523-gene oncology panel identifies actionable tumor variations and improves outcomes
Dorothea Agius and Joe Cottrell talk about developing Illumina’s most innovative and accessible low-throughput platform
| Date | Publication | Title |
|---|---|---|
| Nov 22, 2024 | Fierce Biotech | Illumina previews updated tumor research assay, begins shipping IVD kits |
| Nov 21, 2024 | GenomeWeb | Illumina Incorporates Myriad's Genomic Instability Score Into Updated TSO 500 Cancer Assay |
| Nov 18, 2024 | The Scientist | Benchtop Instruments Bring About a Modern Age of NGS |
| Nov 13, 2024 | Precision Medicine Online | Cancer Study Sees Tailored Treatment, Outcome Boost with Comprehensive Genomic Profiling |
| Nov 12, 2024 | ASCO Daily News | Comprehensive Genomic Profiling Improves Precision Therapy Use and Patient Survival |
At Illumina, we push boundaries. We think beyond the conventional. We dream big. With the energy of so many bright and accomplished people, the opportunities are endless.
Search for JobsIf you are a member of the media:
If you are not a member of the media, please visit Contact Us.
